CD79A and infection: The nasal IgA antibody response was dose dependent, with 14% of participants in group 1 and 31 to 41% in groups 2 to 4, developing nasal IgA responses following vaccination (defined as a >3-fold increase in absolute amount of S-specific IgA over baseline value) regardless of prior vaccination or infection status.